Vasco Marques
Interventional Cardiology · Tampa, FLNPI 1588730113
Payments from drug & device makers
Across 770 payments — averaging $211.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$68K
- Penumbra, Inc.$34K
- Medtronic$33K
- Boehringer Ingelheim International GmbH$10K
- Boehringer Ingelheim Pharma GmbH & Co.kg$4K
- Boston Scientific$3K
- plus $11K from 50 others
What the payments were for
- Consulting fees$6302%
- Speaking & faculty fees$29,52572%
- Travel & lodging$2,2395%
- Food & beverage$8,70821%
- Education$1810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaSeal$16,730
- ClosureFast$15,304
- PRADAXA$630
- MitraClip$422
- CAMZYOS$150
- Impella$127
- Cook Medical Zilver PTX$119
- Edora$112
- Acticor$112
- BioMonitor$112
- Solia$112
- Rivacor$112
How this compares
$162,963 in reported general payments places this provider in the 85th percentile of 623 interventional cardiology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 156 | $181,673 |
| EliquisApixaban | 111 | $110,813 |
| JardianceEmpagliflozin | 52 | $48,597 |
| EntrestoSacubitril/Valsartan | 30 | $41,359 |
| MultaqDronedarone Hcl | 25 | $29,216 |
| Repatha SureclickEvolocumab | 11 | $14,121 |
| Nebivolol Hcl | 50 | $3,180 |
| Amiodarone Hcl | 89 | $2,798 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 13 | $2,500 |
| Flecainide Acetate | 35 | $2,020 |
| Metoprolol Succinate | 105 | $1,897 |
| Ranolazine ErRanolazine | 13 | $1,413 |
| Rosuvastatin Calcium | 59 | $1,228 |
| Olmesartan Medoxomil | 43 | $1,003 |
| Potassium Chloride | 27 | $918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $179 | $181,673156 claims |
| PfizerEliquis | $182 | $110,813111 claims |
| Boehringer IngelheimJardiance | $987 | $48,59752 claims |
| NovartisEntresto | $377 | $41,35930 claims |
| Sanofi-aventis U.S. LLCMultaq | $342 | $29,21625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Tampa
- Saihari SadanandanTampa$558K
- Fadi MatarTampa$448K
- Bibhu MohantyTampa$304K
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.